Chemomab Therapeutics Ltd. CMMB
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a GI/hepatology drug developer. Its lead program, nebokitug, is in Phase 2 for primary sclerosing cholangitis (PSC). Its next catalyst on record is CM-101 (the Product): Chemomab must initiate a Phase 2 trial of CM-101 within 12 months following FDA acceptance of an IND. (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CM-101 (the Product) — Chemomab must initiate a Phase 2 trial of CM-101 within 12 months following FDA acceptance of an IND. (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| nebokitug | primary sclerosing cholangitis (Phase 2 complete; single pivotal Phase 3 design agreed with FDA) | antibody | Phase 2 |
Recent results and decisions
- Oct 16, 2026n/a Chemomab Therapeutics amends domestication merger agreement with Scipher Medicine, reducing Combined Company shares from 10 million to 5 million.
Amendment No. 1 introduced, among other things, a formula-based exchange ratio (the 'Domestication Exchange Ratio') for converting ordinary shares, no par value, of Chemomab ('Chemomab Ordinary Shares,' including those represented by American Depositary Shares ('ADSs')) and options to purchase Chemo
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.